Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject' Cell Therapy Plan

Lineage Cell Therapeutics (LCTX) used a conference call to lay out its manufacturing strategy and development plan for COR1, a wholly owned preclinical cell transplant program targeting corneal endothelial disease. The update is focused on program build-out rather than clinical results, implying limited near-term price impact.

Analysis

Lineage Cell Therapeutics (LCTX) used a conference call to lay out its manufacturing strategy and development plan for COR1, a wholly owned preclinical cell transplant program targeting corneal endothelial disease. The update is focused on program build-out rather than clinical results, implying limited near-term price impact.